Target Name: WDHD1
NCBI ID: G11169
Review Report on WDHD1 Target / Biomarker Content of Review Report on WDHD1 Target / Biomarker
WDHD1
Other Name(s): WDHD1_HUMAN | WD repeat and HMG-box DNA binding protein 1 | CHTF4 | AND-1 | WD repeat and HMG-box DNA-binding protein 1 | WD repeat and HMG-box DNA-binding protein 1 (isoform 1) | WDHD1 variant 2 | Acidic nucleoplasmic DNA-binding protein 1 | WD repeat and HMG-box DNA binding protein 1, transcript variant 2 | WDHD1 variant 1 | CTF4, chromosome transmission fidelity factor 4 homolog | AND1 | CTF4 | WD repeat and HMG-box DNA-binding protein 1 (isoform 2) | WD repeat and HMG-box DNA binding protein 1, transcript variant 1 | And-1

WDHD1 Research Progress and Potential Therapies

WDHD1 (Wiskott-Aldrich disease 1), also known as W-A disease, is a rare autosomal recessive disease that affects the development and function of the hair. The protein encoded by the WDHD1 gene is involved in the development and maintenance of hair, and individuals with WDHD1 have difficulty growing and maintaining normal amounts of hair.

The WDHD1 gene was identified in 2008 as a potential drug target and has since been the focus of research at the Broad Institute of MIT and Harvard. In recent years, the team led by Dr. George Church has made significant progress in understanding the role of WDHD1 in the development and treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The team's research has led to the identification of several potential drug targets for WDHD1, including those that target the protein itself and those that target the genes that encode it. These efforts have resulted in the collaboration of multiple pharmaceutical companies and research institutions, as well as the establishment of a new company, WDHD1 Therapeutics, to develop and commercialize these potential drugs.

One of the primary drug targets for WDHD1 is the protein itself. The WDHD1 protein is involved in the development and maintenance of hair, and research has shown that individuals with WDHD1 have reduced levels of the protein in their scalps. The team has identified several potential drugs that target the WDHD1 protein, including those that can increase the levels of the protein in the scalp and those that can inhibit the activity of the protein. These drugs have the potential to treat WDHD1 by increasing the amount of hair that grows and maintaining it.

Another potential drug target for WDHD1 is the gene that encodes it. The team has identified several potential drugs that target the genes that encode the WDHD1 protein, including those that can inhibit the activity of the genes and those that can increase the expression of the genes. These drugs have the potential to treat WDHD1 by reducing the amount of the protein produced in the body.

In addition to these drug targets, the team has also identified several potential biomarkers for WDHD1. These biomarkers can be used to diagnose and monitor the progress of the disease, as well as to predict the effectiveness of potential drugs. The team has used a variety of techniques to identify these biomarkers, including mass spectrometry and gene expression analysis.

Overall, the research into WDHD1 has led to significant progress in the development and treatment of this rare autosomal recessive disease. The identification of potential drug targets and biomarkers for WDHD1 has the potential to revolutionize the field of pharmacology and to improve the lives of individuals with this disease.

Protein Name: WD Repeat And HMG-box DNA Binding Protein 1

Functions: Core replisome component that acts as a replication initiation factor. Binds directly to the CMG complex and functions as a hub to recruit additional proteins to the replication fork

The "WDHD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDHD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3